Xenoestrogenicity and dental materials.

Faculty of Dentistry, University of British Columbia.
Journal (Canadian Dental Association) (Impact Factor: 0.36). 01/1998; 63(11):833-6.
Source: PubMed


This paper discusses the xenoestrogenicity of dental materials due to 2,2-bis(4-hydroxyphenyl) propane (Bisphenol-A or BPA) and/or its derivatives. Based on a critical review of the pertinent published literature, the author concludes that there is no reason to change the indications for the clinical application of these dental materials.

0 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is controversial whether the dental resinous materials containing 2,2-bis[4-(2-hydroxy-3-methacryloyloxypropoxy)phenyl]propane (Bis-GMA), which is synthesized from the estrogenic compound bisphenol A (BPA), include unreacted BPA and/or can mimic the effects of natural steroid hormones. In the present study, the estrogenic activities of 3 fissure sealants and 5 adhesive resins, which were all unpolymerized, were determined by means of a reporter gene assay, and the relevance of the components to the estrogenicity was investigated. Two commercially available sealants were confirmed to have estrogenic activity, although none of the tested materials contained BPA. In contrast, hydrophobic monomer bisphenol A dimethacrylate (BPA-DMA), which is also estrogenic, was found to be included in these estrogenic sealants in an amount greater than the minimum concentration to show estrogenicity. This suggests that the estrogenicity of the two proprietary sealants was associated with BPA-DMA rather than with BPA.
    Journal of Dental Research 12/2000; 79(11):1838-43. DOI:10.1177/00220345000790110401 · 4.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is a major health concern and is treated based on its hormone dependence. Agents that alter hormone action can have substantial biological effects on prostate cancer development and progression. As such, there is significant interest in uncovering the potential effects of endocrine disrupting compound (EDC) exposure on prostate cancer. The present review is focused on agents that alter hormone action in the prostate and how they may impact cancer growth or treatment.
    Cancer Letters 10/2006; 241(1):1-12. DOI:10.1016/j.canlet.2005.10.006 · 5.62 Impact Factor